Vrdoljak, E <br/><br/>
Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.  [electronic resource] 

 -  Expert opinion on pharmacotherapy  2016 
 - 93-104 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1744-7666 
<br/><br/><label>Standard No.: </label>10.1517/14656566.2016.1107043  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--economics<br/>Carcinoma, Renal Cell--drug therapy<br/>Cost-Benefit Analysis<br/>Economics, Pharmaceutical<br/>Europe, Eastern<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Reimbursement Mechanisms<br/>Turkey